Dipeptide monoester ganciclovir prodrugs for transscleral drug delivery: targeting the oligopeptide transporter on rabbit retina
- PMID: 17803430
- DOI: 10.1089/jop.2006.0150
Dipeptide monoester ganciclovir prodrugs for transscleral drug delivery: targeting the oligopeptide transporter on rabbit retina
Abstract
Purpose: The overall aim of this research work was to evaluate a series of dipeptide monoester prodrugs of an antiviral agent, ganciclovir (GCV), for oligopeptide transporter-targeted transscleral drug delivery to rabbit retina.
Methods: The permeability and enzymatic hydrolysis of dipeptide monoester GCV prodrugs were evaluated using freshly excized rabbit retinal pigment epithelium (RPE)-choroidsclera (RCS) and sclera tissue preparations. Affinity and transport mechanism of these prodrugs and their translocation across RCS were investigated through competitive inhibition studies of [(3)H]glycylsarcosine with the prodrugs.
Results: The transport of glycylsarcosine was found to be saturable (K(m) = 1.21 +/- 0.41 mM, V(max) = 15.89 +/- 1.54 pmoles/min/cm(2)), pH, temperature, and energy dependant. Dipeptides, angiotensin converting enzyme inhibitors, and a beta-lactum antibiotic strongly inhibited the transport of glycylsarcosine indicating the functional presence of oligopeptide transport (OPT) system on the RPE. Dipeptide prodrugs (valine-valine-GCV, glycine-valine-GCV, and tyrosine-valine-GCV), and valine-GCV demonstrate a high enzymatic stability and affinity toward the retinal OPT system. The transport of the prodrugs was significantly inhibited ( approximately 50%) in the presence of glycylsarcosine. The rank order of scleral permeability was Gly-Val-GCV approximately GCV>Val-GCV>Tyr-Val-GCV approximately Val-Val-GCV. The RCS permeability values of Val-GCV (3.29 +/- 0.09 x 10(6)cm/s), Val-Val-GCV (4.14 +/- 0.33 x 10(6)cm/s), Gly-Val-GCV (3.40 +/- 0.47 x 10(6)cm/s) and Tyr-Val-GCV (3.08 +/- 0.29 x 10(6)cm/s) were two-fold higher than that of GCV (1.61 +/- 0.06 x 10(6)cm/s).
Conclusions: The dipeptide monoester GCV prodrugs, owning to higher lipophilicity and OPT-mediated translocation across RPE, appear to be promising candidates in the treatment of ocular cytomegalovirus infections following an episcleral administration.
Similar articles
-
Vitreal pharmacokinetics of dipeptide monoester prodrugs of ganciclovir.J Ocul Pharmacol Ther. 2006 Aug;22(4):231-41. doi: 10.1089/jop.2006.22.231. J Ocul Pharmacol Ther. 2006. PMID: 16910863
-
Dipeptide monoester ganciclovir prodrugs for treating HSV-1-induced corneal epithelial and stromal keratitis: in vitro and in vivo evaluations.J Ocul Pharmacol Ther. 2005 Dec;21(6):463-74. doi: 10.1089/jop.2005.21.463. J Ocul Pharmacol Ther. 2005. PMID: 16386088
-
Corneal absorption and anterior chamber pharmacokinetics of dipeptide monoester prodrugs of ganciclovir (GCV): in vivo comparative evaluation of these prodrugs with Val-GCV and GCV in rabbits.J Ocul Pharmacol Ther. 2006 Dec;22(6):465-76. doi: 10.1089/jop.2006.22.465. J Ocul Pharmacol Ther. 2006. PMID: 17238815
-
Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling.Adv Drug Deliv Rev. 2006 Nov 15;58(11):1164-81. doi: 10.1016/j.addr.2006.07.025. Epub 2006 Sep 16. Adv Drug Deliv Rev. 2006. PMID: 17069929 Review.
-
Transscleral drug delivery to the retina and choroid.Prog Retin Eye Res. 2002 Mar;21(2):145-51. doi: 10.1016/s1350-9462(01)00018-0. Prog Retin Eye Res. 2002. PMID: 12062532 Review.
Cited by
-
Recent perspectives in ocular drug delivery.Pharm Res. 2009 May;26(5):1197-216. doi: 10.1007/s11095-008-9694-0. Epub 2008 Aug 29. Pharm Res. 2009. PMID: 18758924 Free PMC article. Review.
-
Prodrug strategies in ocular drug delivery.Med Chem. 2012 Jul;8(4):753-68. doi: 10.2174/157340612801216283. Med Chem. 2012. PMID: 22530907 Free PMC article. Review.
-
Ocular drug delivery.AAPS J. 2010 Sep;12(3):348-60. doi: 10.1208/s12248-010-9183-3. Epub 2010 May 1. AAPS J. 2010. PMID: 20437123 Free PMC article. Review.
-
Hypoxia alters ocular drug transporter expression and activity in rat and calf models: implications for drug delivery.Mol Pharm. 2013 Jun 3;10(6):2350-61. doi: 10.1021/mp3007133. Epub 2013 May 22. Mol Pharm. 2013. Retraction in: Mol Pharm. 2015 Jul 6;12(7):2559. doi: 10.1021/acs.molpharmaceut.5b00367. PMID: 23607566 Free PMC article. Retracted.
-
A comprehensive insight on ocular pharmacokinetics.Drug Deliv Transl Res. 2016 Dec;6(6):735-754. doi: 10.1007/s13346-016-0339-2. Drug Deliv Transl Res. 2016. PMID: 27798766 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources